CRISPR gene-editing therapy approved by FDA for sickle cell treatment
The FDA approved a gene-editing therapy, known as CRISPR, as a treatment for sickle cell disease, which impacts more than 100,000 Americans.
Watch CBS News
The FDA approved a gene-editing therapy, known as CRISPR, as a treatment for sickle cell disease, which impacts more than 100,000 Americans.
Sickle cell disease affects approximately 100,000 people in the U.S., predominantly people of color.
